

Table S3. General patient information of 33 patients treated with BTK inhibitor

Sample ID	Subtype	Stage	Age	Sex	BTK inhibitor
G003	DLBCL	IV	58	Female	Ibrutinib
G005	tMZL	IV	59	Female	Zanubrutinib
G006	DLBCL	IV	65	Male	Ibrutinib
B001	DLBCL	II	36	Female	Ibrutinib
B002	MCL	IV	56	Male	Zanubrutinib
B003	MCL	IV	73	Male	BTKi in Clinical trail
B004	MCL	IV	55	Female	Zanubrutinib
B005	MCL	IV	62	Male	LOXO-305
B006	MCL	IV	65	Male	Orelabrutinib
B007	MCL	IV	61	Male	BTKi in Clinical trail
B008	MCL	IV	45	Female	Orelabrutinib
B009	MCL	IV	50	Male	BTKi in Clinical trail
B010	MCL	IV	55	Male	Acalabrutinib
B011	MCL	III	65	Male	LOXO-305
B012	MCL	IV	72	Male	Orelabrutinib
B013	MCL	IV	43	Female	BTKi in Clinical trail
B014	MCL	IV	55	Male	BTKi in Clinical trail
B015	MCL	IV	45	Male	BTKi in Clinical trail
B016	MCL	IV	49	Male	BTKi in Clinical trail
B017	MCL	IV	57	Male	BTKi in Clinical trail
B018	MCL	IV	68	Male	BTKi in Clinical trail
B019	MCL	IV	68	Male	BTKi in Clinical trail
B020	MCL	IV	68	Male	BTKi in Clinical trail
B021	MCL	IV	67	Male	BTKi in Clinical trail
B022	MZL	IV	65	Female	Orelabrutinib
B023	MZL	IV	51	Male	Orelabrutinib
B024	tMZL	IV	45	Male	Zanubrutinib
B025	tCLL/SLL	II	48	Male	Zanubrutinib
B026	CLL/SLL	IV	45	Male	Zanubrutinib
B027	CLL/SLL	IV	51	Male	Ibrutinib
S001	CLL/SLL	IV	69	Male	Ibrutinib
S002	MCL	IV	67	Female	Ibrutinib
S003	MCL	IV	58	Female	Ibrutinib

DLBCL, Diffuse large B cell lymphoma; MCL, Mantle cell lymphoma; MZL, Marginal Zone Lymphoma; tMZL, transformed MZL; CLL/SLL, Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma; tCLL/SLL, transformed CLL/SLL.